MAPT and Alzheimer disease: In what way APOE4 contributes to AD pathology is still under investigation, but experimental studies have demonstrated that APOE4 exacerbates the Aβ plaque and tau burden and disrupts glial immunomodulating functions leading to chronic inflammation [10].